Latent Labs Emerges from Stealth with $50M to Advance AI-Driven Drug Discovery
Slice of Healthcare Team
02/19/2025
Key Highlights
- Latent Labs exits stealth with $50M total funding, including a $40M Series A co-led by Radical Ventures and Sofinnova Partners.
- Founded by Dr. Simon Kohl, former co-lead of DeepMind’s protein design team and key contributor to AlphaFold2.
- Investors include Google Chief Scientist Jeff Dean, Transformer architecture inventor Aidan Gomez, and ElevenLabs founder Mati Staniszewski.
- Latent Labs' AI platform enables de novo protein design, expediting drug development and unlocking new therapeutic targets.
- Operates in London and San Francisco, combining AI innovation with in-lab experimental validation.
Source: Business Wire
Notable Quotes
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
